RxSight, Inc. - Common Stock (RXST)
26.71
-0.14 (-0.54%)
Rxsight Inc is a healthcare technology company that focuses on enhancing vision correction through its innovative approach to personalized refractive surgery
The company develops advanced systems that utilize sophisticated algorithms and proprietary software to optimize intraocular lenses for patients undergoing cataract surgery. By combining data-driven insights with precision eye care, Rxsight aims to improve visual outcomes for patients, ultimately advancing the standards of treatment in the ophthalmic field. Their commitment to personalized medicine is reflected in their ongoing research and development efforts to create more effective solutions for vision-related challenges.
Previous Close | 26.86 |
---|---|
Open | 26.95 |
Bid | 26.66 |
Ask | 26.77 |
Day's Range | 26.32 - 27.08 |
52 Week Range | 26.17 - 66.54 |
Volume | 154,691 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 550,662 |
News & Press Releases

Via Benzinga · February 26, 2025

ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 31, 2024.
By RxSight, Inc. · Via GlobeNewswire · February 25, 2025

ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024 after the market close on Tuesday, February 25, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
By RxSight, Inc. · Via GlobeNewswire · February 11, 2025

ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQRXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance.
By RxSight, Inc. · Via GlobeNewswire · January 12, 2025

Via Benzinga · December 20, 2024

ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQRXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.
By RxSight, Inc. · Via GlobeNewswire · January 2, 2025

Via Benzinga · December 20, 2024

Via Benzinga · December 11, 2024

ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQRXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024.
By RxSight, Inc. · Via GlobeNewswire · November 7, 2024

Via Benzinga · September 13, 2024

Via Benzinga · August 6, 2024

Via Benzinga · October 29, 2024

ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
By RxSight, Inc. · Via GlobeNewswire · October 24, 2024

ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQRXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September.
By RxSight, Inc. · Via GlobeNewswire · August 22, 2024

On Monday, RxSight stock earned a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91.
Via Investor's Business Daily · August 19, 2024

RXST stock results show that RxSight beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 5, 2024

Via Benzinga · August 6, 2024

We have all of the biggest pre-market stock movers that traders are going to want to read about on Tuesday!
Via InvestorPlace · August 6, 2024

Via Benzinga · August 6, 2024

Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now.
Via InvestorPlace · August 5, 2024

ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQRXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024.
By RxSight, Inc. · Via GlobeNewswire · August 5, 2024

ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQRXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
By RxSight, Inc. · Via GlobeNewswire · July 22, 2024